SCHEMBL1848418

SCHEMBL1848418

O=c1cc(-c2ccc(F)cc2)[nH]c2c(O)c(O)ccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSV O60911 1/20 0.52
CTSL P07711 1/20 0.52
ADORA2A P29274 1/20 0.50
ADORA1 P30542 1/20 0.50
ERCC1 P07992 1/20 0.50
ERCC4 Q92889 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 3/20 0.49
HPGD P15428 3/20 0.48
LMNA P02545 2/20 0.48
CYP1A1 P04798 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP1B1 Q16678 1/20 0.47
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GSK3B P49841 1/20 0.42
SRC P12931 1/20 0.41
PRKACA P17612 1/20 0.41
PRKACG P22612 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1976213 0.99 CTSV (0.51) CTSVCTSLADORA2AADORA1ERCC1
SCHEMBL312031 0.88 TERT (0.49) ADORA2AMEN1KMT2AKDM4EHPGD
SCHEMBL1849234 0.85 HPGD (0.53) CTSVCTSLADORA2AADORA1MEN1
Bromide SCHEMBL1978677 0.84 HPGD (0.51) CTSVCTSLADORA2AADORA1MEN1
SCHEMBL12588956 0.82 ALDH1A1 (0.57) MEN1KMT2AKDM4EHPGDLMNA
SCHEMBL12588953 0.82 QPCT (0.43) ADORA2AADORA1MEN1KMT2AKDM4E
SCHEMBL340804 0.77 CTSV (0.52) CTSVCTSLADORA2AADORA1ERCC1
SCHEMBL311330 0.73 KMT2A (0.43) CTSVCTSLADORA2AADORA1MEN1
SCHEMBL313903 0.72 ALDH1A1 (0.68) CTSVCTSLADORA2AADORA1MEN1
SCHEMBL14702307 0.72 CYP1A1 (0.55) CTSVCTSLADORA2AADORA1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9895344-B2 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof EMORY UNIVERSITY (US) 2018-02-20 US disclosed
US-9895344-B2 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof EMORY UNIVERSITY (US) 2018-02-20 US disclosed
EP-2579870-B1 TRKB AGONISTS AND METHODS OF USE UNIV EMORY (US) 2018-02-14 EP disclosed
EP-2579870-B1 TRKB AGONISTS AND METHODS OF USE UNIV EMORY (US) 2018-02-14 EP disclosed
US-9504674-B2 TrkB agonists and methods of use EMORY UNIVERSITY (US) 2016-11-29 US disclosed
US-9504674-B2 TrkB agonists and methods of use EMORY UNIVERSITY (US) 2016-11-29 US disclosed
US-9504674-B2 TrkB agonists and methods of use EMORY UNIVERSITY (US) 2016-11-29 US disclosed
CN-102143744-B Application of 7, 8-dihydroxyflavone and derivatives thereof in preparing medicament for treating depression 爱默蕾大学 2016-08-31 CN disclosed
CN-105832717-A Treatment of various disorders with 7,8-dihydroxyflavone and derivatives thereof 爱默蕾大学 2016-08-10 CN disclosed
US-20150174107-A1 TRKB AGONISTS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-06-25 US disclosed
US-20130040947-A1 TRKB AGONISTS AND METHODS OF USE EMORY UNIVERSITY (US) 2013-02-14 US disclosed
US-20130040947-A1 TRKB AGONISTS AND METHODS OF USE EMORY UNIVERSITY (US) 2013-02-14 US disclosed
US-20130040947-A1 TRKB AGONISTS AND METHODS OF USE EMORY UNIVERSITY (US) 2013-02-14 US disclosed
WO-2011156479-A9 TRKB AGONISTS AND METHODS OF USE EMORY UNIVERSITY (US) 2012-05-31 WO disclosed
WO-2011156479-A2 TRKB AGONISTS AND METHODS OF USE EMORY UNIVERSITY (US) 2011-12-15 WO disclosed
US-20110144196-A1 TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF EMORY UNIVERSITY (US) 2011-06-16 US disclosed
US-20110144196-A1 TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF EMORY UNIVERSITY (US) 2011-06-16 US disclosed
EP-2323649-A2 TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF Emory University (US) 2011-05-25 EP disclosed
WO-2010011836-A2 TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF EMORY UNIVERSITY (US) 2010-01-28 WO disclosed
WO-2010011836-A2 TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF EMORY UNIVERSITY (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040947-A1 TRKB AGONISTS AND METHODS OF USE NTRK2, BDNF, NTRK1 CTSV 1920/4885CTSL 2757/4885ADORA2A 362/4885
US-20150174107-A1 TRKB AGONISTS AND METHODS OF USE NTRK2, BDNF, NTRK1 CTSV 1914/4885CTSL 2777/4885ADORA2A 339/4885
US-20110144196-A1 TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF NTRK2, BDNF, HTR7 CTSV 2863/4885CTSL 3333/4885ADORA2A 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.